QAD Hosts Forum to Prepare Life Sciences Manufacturers for Industry Reform
28 Settembre 2010 - 2:06PM
Business Wire
QAD Inc. (NASDAQ:QADI), a leading provider of enterprise
software and services for global manufacturers, today announced the
launch of its New York City Life Sciences Forum at the Grand Havana
Room on October 7, to provide a forum for Life Sciences
manufacturers to learn how to navigate and adapt to impending
healthcare industry changes, while building market strength through
technology adoption.
By 2015, Life Sciences manufacturers and distributors will be
expected to comply with California’s ePedigree Law, mandating mass
serialization on the smallest saleable unit-level. To prepare Life
Sciences manufacturers, QAD and its panel of experts from Excellis
Consulting Corporation, United Drug PLC, and J.P. Morgan Chase,
will lead an invitation-only audience through a series of
presentations and open discussion on the impending changes to
serialization, ePedigree and healthcare reform, and how to leverage
technology to transform these challenges into market
opportunities.
Greg Cathcart, CEO at Excellis, and Rick Seibert, vice president
of Business Development at United Drug PLC, will provide a keynote
presentation on the evolving global regulatory landscape
surrounding serialization and ePedigree.
“Many biotech and pharmaceutical companies are already moving
aggressively to serialize their key products,” noted Riya Cao,
director for Life Sciences at QAD. “These manufacturers recognize
how serialization provides tractability and accountability in the
global supply chain, mitigates risk and counterfeits, protects
revenue and builds brand trust.”
A representative of Informatics at Forest Laboratories will
present to the forum on the challenges Life Sciences companies face
with the new Health Care Reform bill.
Completing the session, John DiFucci, managing director at J.P.
Morgan Chase, will show how Life Sciences companies can meet
regulatory requirements while driving down costs leveraging QAD
Enterprise Applications On Demand.
About the NYC Life Sciences Forum Presenters
Greg Cathcart, CEO at Excellis Consulting Corporation, has more
than 25 years in the Life Sciences industry. He currently leads the
Excellis team in support of its clients in the areas such as supply
chain strategy and execution, and is the sponsor of the
www.globaltrackandtrace.org consortium, an industry run consortium
focused on the global serialization needs of the industry.
Rick Seibert, vice president of Business Development at United
Drug Plc, boasts more than 25 years’ experience in the medical
device, surgical instrument and pharmaceutical packaging and
services industries. He is an expert in strategic planning,
marketing/business development, project management, business
process improvement and product development, and holds multiple
undergraduate and graduate degrees and certifications.
John DiFucci, managing director at J.P. Morgan, is a software
industry veteran. He is an expert in the infrastructure software
industry, including the integration, application development,
systems and performance management, business intelligence,
security, and storage. He holds multiple degrees and licenses.
About QAD
QAD is a leading provider of enterprise applications for global
manufacturing companies specializing in automotive, consumer
products, electronics, food and beverage, industrial and life
science products. QAD applications provide critical functionality
for managing manufacturing resources and operations within and
beyond the enterprise, enabling global manufacturers to collaborate
with their customers, suppliers and partners to make and deliver
the right product, at the right cost and at the right time. For
more information about QAD, telephone +1 805-566-6000, or visit the
QAD web site at www.qad.com.
“QAD” is a registered trademark of QAD Inc. All other products
or company names herein may be trademarks of their respective
owners.
Note to Investors: This press release contains certain
forward-looking statements made under the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. A number
of risks and uncertainties could cause actual results to differ
materially from those in the forward-looking statements. These
risks include, but are not limited to, evolving demand for the
company's software products and products that operate with the
company's products; the company's ability to sustain license and
service demand; the company's ability to leverage changes in
technology; the company's ability to sustain customer renewal rates
at current levels; the publication of opinions by industry and
financial analysts about the company, its products and technology;
the reliability of estimates of transaction and integration costs
and benefits; the entry of new competitors or new offerings by
existing competitors and the associated announcement of new
products and technological advances by them; delays in localizing
the company's products for new or existing markets; the ability to
recruit and retain key personnel; delays in sales as a result of
lengthy sales cycles; changes in operating expenses, pricing,
timing of new product releases, the method of product distribution
or product mix; timely and effective integration of newly acquired
businesses; general economic conditions; exchange rate
fluctuations; and, the global political environment. In addition,
revenue and earnings in the enterprise resource planning (ERP)
software industry are subject to fluctuations. Software license
revenue, in particular, is subject to variability with a
significant proportion of revenue earned in the last month of each
quarter. Given the high margins associated with license revenue,
modest fluctuations can have a substantial impact on net income.
Investors should not use any one quarter's results as a benchmark
for future performance. For a more detailed description of the risk
factors associated with the company and the industries in which it
operates, please refer to the company's Annual Report on Form 10-K
for fiscal 2010 ended January 31, 2010.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6445480&lang=en.
Grafico Azioni Qad Inc. (MM) (NASDAQ:QADI)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Qad Inc. (MM) (NASDAQ:QADI)
Storico
Da Lug 2023 a Lug 2024